8 / 8
Page 48
Notes:
Journal of Clinical & Experimental Pathology | ISSN: 2161-0681 | Volume 8
Breast Pathology and Cancer Diagnosis
6
th
World Congress and Expo on
July 25-26, 2018 | Vancouver, Canada
Medicinal Chemistry and Rational Drugs
20
th
International Conference on
&
Development of potent autoinducer-2 quorum-sensing inhibitors equipped with novel bicyclic brominated
furanones against bacterial biofilm formation
B
iofilm formation is one of the critical factors affecting bacterial survival in association with bacterial virulence factors. It is
effectively regulated through a process called quorum sensing, which is an intra- and interspecies bacterial communication
system. According to changes in cell deinsity and species complexity, complex biological responses are triggered through the
quorum sensing. Chronic inflammation of the periodontium is one of the most common inflammatory diseases, which is in part
caused by subgingival biofilm formation from periodontopathogens. Particularly, the early and late colonizers in periodontal
biofilms are linked together by Fusobacterium nucleatum, which is thus regarded as a major co-aggregation bridge organism
in forming aqnd growing subgingival biofilms. We have previously shown that autoinducer-2 (AI-2) of F. Nucleatum, the
intergeneric quorum-sensing signal molecule, can be a possible target for the inhibition of periodontal biofilm formation, since
it plays a key role in intra- and interspecies interactions of periodontopathogens. Recently, inhibition of biofilm formation via
AI-2 by novel brominated furanones originated frommarine natural products such as those frommacroalga Delisea pulchra has
been reported, and further studies toward the goal of increasing the inhibition effect have been conducted. Herein, we describe
the synthesis and quorum sensing inhibitory activities of new bromofuranone analogs in relation with biofilm formation by
periodontopathogens such as
F. nucleatum, Porphyromonas gingivalis,
and Tannerella forsythia.
Biography
B Moon Kim has completed his PhD and postdoctoral studies at M.I.T. After 5 year experience at Merck Research Laboratories in USA, he took a faculty position
at the Chemistry Department of Seoul Naitonal University in Seoul, Korea. He was Chemistry Department Chair and Director of the BK21 Chemistry & Molecular
Engineering Division at SNU. He has published more than 120 papers and 25 patents and has been serving as an editorial board member of Bioorganic Medicinal
Chemistry and Bioorgnaic & Medicinal Chemistry Letters and an editor-in-chief of Bulletin of the Korean Chemical Society.
kimbm@snu.ac.krB Moon Kim
Seoul National University, Republic of Korea
B Moon Kim, J Clin Exp Pathol 2018, Volume 8
DOI: 10.4172/2161-0681-C3-050